Second-line systemic therapy in patients with recurrent or metastatic adenoid cystic carcinoma

被引：0
|
作者：
Kadowaki, Shigenori [1 ]
Nakazawa, Taiko [1 ]
Ogata, Takatsugu [1 ]
Matsubara, Yuki [1 ]
Nozawa, Kazuki [1 ]
Kato, Kyoko [1 ]
Narita, Yukiya [1 ]
Honda, Kazunori [1 ]
Masuishi, Toshiki [1 ]
Bando, Hideaki [1 ]
Ando, Masashi [1 ]
Hanai, Nobuhiro [2 ]
Muro, Kei [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[2] Aichi Canc Ctr Hosp, Dept Head & Neck Surg, Nagoya, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.05.621
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO22-6
引用
收藏
页码：S312 / S312
页数：1
相关论文
共 50 条
  • [21] First-and second-line therapy for metastatic urothelial carcinoma of the bladder
    Yafi, F. A.
    North, S.
    Kassouf, W.
    CURRENT ONCOLOGY, 2011, 18 (01) : E25 - E34
  • [22] Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies
    Salah, Samer
    Lee, Jae-Lyun
    Rozzi, Antonio
    Kitamura, Hiroshi
    Matsumoto, Kazumasa
    Vis, Daniel J.
    Srinivas, Sandy
    Morales-Barrera, Rafael
    Carles, Joan
    Al-Rimawi, Dalia
    Lee, Soonil
    Kim, Ki Hong
    Izumi, Kouji
    Lewin, Jeremy
    CLINICAL GENITOURINARY CANCER, 2017, 15 (04) : E563 - E571
  • [23] Preliminary analysis of FOLFIRI regimen with or without bevacizumab as second-line systemic therapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.
    Zhao, Xiaoying
    Wang, Chen Chen
    Zhang, Wen
    Zhu, Xiaodong
    Guo, Weijian
    Chen, Zhi-Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [24] Efficacy and safety of apatinib as second-line or beyond therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Qin, You
    Ding, Qian
    Xu, Xinhua
    Cao, Fengjun
    Ning, Siqing
    Zhou, Haibo
    Chen, Guiming
    Huang, Jing
    Peng, Gang
    Yang, Kunyu
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Phase II study of axitinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma
    Ho, Alan Loh
    Sherman, Eric Jeffrey
    Fury, Matthew G.
    Baxi, Shrujal S.
    Haque, Sofia
    Sima, Camelia S.
    Antonescu, Cristina R.
    Katabi, Nora
    Pfister, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Effect of Systemic Inflammation on Survival in Patients With Metastatic Renal Cell Carcinoma Receiving Second-line Molecular-targeted Therapy
    Ishihara, Hiroki
    Kondo, Tsunenori
    Yoshida, Kazuhiko
    Omae, Kenji
    Takagi, Toshio
    Iizuka, Junpei
    Tanabe, Kazunari
    CLINICAL GENITOURINARY CANCER, 2017, 15 (04) : 495 - 501
  • [27] A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma (ACC).
    Dillon, Patrick Michael
    Petroni, Gina R.
    Moskaluk, Chris
    Fracasso, Paula M.
    Douvas, Michael G.
    Perez, Jose Ricardo
    Varhegyi, Nikole
    Zaja-Milatovic, Snjezana
    Thomas, Christopher Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma
    Tchekmedyian, Vatche
    Sherman, Eric J.
    Dunn, Lara
    Tran, Crystal
    Baxi, Shrujal
    Katabi, Nora
    Antonescu, Cristina R.
    Ostrovnaya, Irina
    Haque, Sofia S.
    Pfister, David G.
    Ho, Alan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18) : 1529 - 1537
  • [29] Second-line treatment of metastatic prostatic carcinoma
    D. W. W. Newling
    Urological Research, 1997, 25 : S73 - S78
  • [30] Second-Line Therapies in Metastatic Urothelial Carcinoma
    Narayanan, Sujata
    Harshman, Lauren C.
    Srinivas, Sandy
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2015, 29 (02) : 341 - +
12345